Ari Breiner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ari Breiner has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Vera Bril
University Health Network
9 shared publications - Jodi Warman-Chardon
The Ottawa Hospital Research Institute, Ottawa, Canada
8 shared publications - Pierre Raymond Bourque
Division of Neurology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada
8 shared publications - Carolina Barnett
Division of Neurology, Department of Medicine, University of Toronto and University Health Network, Ontario, Canada
7 shared publications - Hans Dieter Katzberg
University of Toronto
6 shared publications - Alon Abraham
Neuromuscular Diseases Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
5 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Springer Nature in Health and Quality of Life Outcomes
Quality of life of individuals with neuromuscular disease: a national cross-sectional survey
- 11 November 2026
- Published by Springer Nature in Health and Quality of Life Outcomes
Open AccessQuality of life of individuals with neuromuscular disease: a national cross-sectional survey
- Open Access
- 18 September 2026
- Published by SAGE Publications in Journal of Neuromuscular Diseases
Cramps as the initial presentation of CANVAS/RFC1-related disorder
Biallelic mutations in the RFC1 gene are associated with CANVAS syndrome (cerebellar ataxia, neuropathy and vestibular areflexia). Peripheral nerve involvement in the form of sensory neuronopathy and small fiber autonomic axonopathy is a core feature of its presentation. Motor manifestations, in the other hand, remain poorly understood and incompletely characterized. We present two cases referred for evaluation of muscle cramps as the main clinical symptom, who were ultimately diagnosed with CANVAS. We also conducted a literature review on cramps and other motor manifestations as the predominant symptom in this condition. This study highlights the recognition of cramps as a possible isolated motor manifestation, expanding the phenotypic spectrum of RFC1 -related disease and the need of a high index of suspicion to accurately identified the condition.
- 18 September 2026
- Published by SAGE Publications in Journal of Neuromuscular Diseases
Open AccessCramps as the initial presentation of CANVAS/RFC1-related disorder
Biallelic mutations in the RFC1 gene are associated with CANVAS syndrome (cerebellar ataxia, neuropathy and vestibular areflexia). Peripheral nerve involvement in the form of sensory neuronopathy and small fiber autonomic axonopathy is a core feature of its presentation. Motor manifestations, in the other hand, remain poorly understood and incompletely characterized. We present two cases referred for evaluation of muscle cramps as the main clinical symptom, who were ultimately diagnosed with CANVAS. We also conducted a literature review on cramps and other motor manifestations as the predominant symptom in this condition. This study highlights the recognition of cramps as a possible isolated motor manifestation, expanding the phenotypic spectrum of RFC1 -related disease and the need of a high index of suspicion to accurately identified the condition.
- Open Access
- 3 December 2025
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-3
Case Series Assessing the Use of Levetiracetam for Gait Improvement in Primary Lateral Sclerosis
In this retrospective case series, we present two patients with primary lateral sclerosis (PLS) and spasticity-related gait impairment. Both patients were assessed with 6-min walk tests (6MWT) and timed up and go (TUG) at baseline and after 4 weeks of oral levetiracetam. Following levetiracetam therapy, Patient 1 improved 27.3% (148.5 to 189 m) on 6MWT and 26.1% (23–17 s) on TUG. Patient 2 improved 18% (90 m in 4:29 min to 112 m in 6 min) on 6MWT and 10% (46–41 s) on TUG. Larger prospective trials of levetiracetam for spasticity and gait may be considered in PLS.
- 3 December 2025
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-3
Open AccessCase Series Assessing the Use of Levetiracetam for Gait Improvement in Primary Lateral Sclerosis
In this retrospective case series, we present two patients with primary lateral sclerosis (PLS) and spasticity-related gait impairment. Both patients were assessed with 6-min walk tests (6MWT) and timed up and go (TUG) at baseline and after 4 weeks of oral levetiracetam. Following levetiracetam therapy, Patient 1 improved 27.3% (148.5 to 189 m) on 6MWT and 26.1% (23–17 s) on TUG. Patient 2 improved 18% (90 m in 4:29 min to 112 m in 6 min) on 6MWT and 10% (46–41 s) on TUG. Larger prospective trials of levetiracetam for spasticity and gait may be considered in PLS.
- Open Access
- 12 November 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (4) , 832-839
MT-ATP6 variant as a cause of adult-onset hereditary spastic paraparesis: A case report and literature review
Background: Hereditary spastic paraplegia (HSP) is a heterogenous group of rare genetic disorders characterized by progressive corticospinal and dorsal spinal cord axonal degeneration manifesting as muscle weakness and spasticity of the lower extremities. Over 98% of solved HSP cases are caused by pathogenic variants in the nuclear DNA. Case: We report a family carrying the m.9035T > C [p.(Leu170Pro)] pathogenic variant in the mitochondrial MT - ATP6 gene in the setting of maternally inherited, late-onset HSP. The proband (age 67 years) presented with classical, late-onset, pure HSP. Her affected daughter (age 39 years) developed late-onset, complex HSP, with asymmetrical axonal sensorimotor polyneuropathy. Her second daughter (age 46 years) carried the same pathogenic variant with high heteroplasmy but was clinically unaffected at last assessment, suggesting age-dependent or incomplete penetrance. Summary of literature: The substitution of a leucine for a proline affects a highly conserved transmembrane helix of the subunit “a” at a key functional domain in the mitochondrial ATP synthase complex. The m.9035T > C variant has been reported in several families presenting with common phenotypic presentations of ATP6-related disorders such as maternally inherited Leigh syndrome (MILS) and the syndrome of neuropathy, ataxia, and retinitis pigmentosa (NARP). HSP is a rare presentation in ATP6-related disorders; mitochondrial ATP6-induced HSP has previously been published in only one family carrying a homoplasmic m.9176T > C [p.(Leu217Pro)] variant. Conclusion: This report highlights the role of MT-ATP6 pathogenic variants in complex and pure HSP and raises the relevance of genetic testing of MT-ATP6 in undiagnosed cases of sporadic or maternally inherited HSP.
- 12 November 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (4) , 832-839
Open AccessMT-ATP6 variant as a cause of adult-onset hereditary spastic paraparesis: A case report and literature review
Background: Hereditary spastic paraplegia (HSP) is a heterogenous group of rare genetic disorders characterized by progressive corticospinal and dorsal spinal cord axonal degeneration manifesting as muscle weakness and spasticity of the lower extremities. Over 98% of solved HSP cases are caused by pathogenic variants in the nuclear DNA. Case: We report a family carrying the m.9035T > C [p.(Leu170Pro)] pathogenic variant in the mitochondrial MT - ATP6 gene in the setting of maternally inherited, late-onset HSP. The proband (age 67 years) presented with classical, late-onset, pure HSP. Her affected daughter (age 39 years) developed late-onset, complex HSP, with asymmetrical axonal sensorimotor polyneuropathy. Her second daughter (age 46 years) carried the same pathogenic variant with high heteroplasmy but was clinically unaffected at last assessment, suggesting age-dependent or incomplete penetrance. Summary of literature: The substitution of a leucine for a proline affects a highly conserved transmembrane helix of the subunit “a” at a key functional domain in the mitochondrial ATP synthase complex. The m.9035T > C variant has been reported in several families presenting with common phenotypic presentations of ATP6-related disorders such as maternally inherited Leigh syndrome (MILS) and the syndrome of neuropathy, ataxia, and retinitis pigmentosa (NARP). HSP is a rare presentation in ATP6-related disorders; mitochondrial ATP6-induced HSP has previously been published in only one family carrying a homoplasmic m.9176T > C [p.(Leu217Pro)] variant. Conclusion: This report highlights the role of MT-ATP6 pathogenic variants in complex and pure HSP and raises the relevance of genetic testing of MT-ATP6 in undiagnosed cases of sporadic or maternally inherited HSP.
- Open Access
- 26 October 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (36) , E1211-E1213
L’intégration des tests génétiques dans la prise en charge de la patientèle atteinte de sclérose latérale amyotrophique : un moment critique
- 26 October 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (36) , E1211-E1213
Open AccessL’intégration des tests génétiques dans la prise en charge de la patientèle atteinte de sclérose latérale amyotrophique : un moment critique
- Open Access
- 21 September 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (31) , E1006-E1007
Integrating genetic testing into management of all patients with amyotrophic lateral sclerosis: a critical juncture
- 21 September 2025
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 197 (31) , E1006-E1007
Open AccessIntegrating genetic testing into management of all patients with amyotrophic lateral sclerosis: a critical juncture
- 5 July 2025
- Vol. 182, 161-196
Epidemiology of myasthenia gravis.
MG epidemiology may provide clues to disease etiology and pathogenesis. It is crucial for health planning and to estimate societal needs for health care resources. Recent high-quality studies have found an annual MG incidence of approximately 20 per million person-years, and a prevalence of approximately 25 per 100,000 population. Geographical variation reflects differences in case finding and diagnostic tools, but also a multitude of genetic and environmental etiological and risk factors. MG prevalence has increased in recent years because of more elderly people in the general population, improved case finding, and improved MG treatment with reduced mortality. In populations with optimal treatment, there is only a slightly increased mortality risk with MG. There are marked variations among MG disease subgroups regarding epidemiology. MuSK MG is more common in the Mediterranean area, juvenile MG is most common in China, whereas late onset MG with AChR antibodies is a subtype that has increased in incidence and prevalence globally.
- 5 July 2025
- Vol. 182, 161-196
Epidemiology of myasthenia gravis.
MG epidemiology may provide clues to disease etiology and pathogenesis. It is crucial for health planning and to estimate societal needs for health care resources. Recent high-quality studies have found an annual MG incidence of approximately 20 per million person-years, and a prevalence of approximately 25 per 100,000 population. Geographical variation reflects differences in case finding and diagnostic tools, but also a multitude of genetic and environmental etiological and risk factors. MG prevalence has increased in recent years because of more elderly people in the general population, improved case finding, and improved MG treatment with reduced mortality. In populations with optimal treatment, there is only a slightly increased mortality risk with MG. There are marked variations among MG disease subgroups regarding epidemiology. MuSK MG is more common in the Mediterranean area, juvenile MG is most common in China, whereas late onset MG with AChR antibodies is a subtype that has increased in incidence and prevalence globally.
- Open Access
- 3 May 2024
- Published by Wiley in Muscle & Nerve
- Vol. 70 (1) , 101-110
Whole‐body magnetic resonance neurography in patients with chronic inflammatory demyelinating polyneuropathy
Introduction/Aims: Whole‐body magnetic resonance neurography (MRN) is an imaging modality that shows peripheral nerve signal change in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). We aimed to explore the diagnostic potential of whole‐body MRN and its potential as a monitoring tool after immunotherapy in treatment‐naïve CIDP patients.Methods: Whole‐body MRN using coronal 3‐dimensional short tau inversion recovery (STIR) sampling perfection with application‐optimized contrasts by using different flip angle evolution (SPACE) techniques was performed in patients being investigated for CIDP and in healthy controls. Baseline clinical neuropathy scales and electrophysiologic parameters were collected, and MRN findings were compared before and after CIDP treatment.Results: We found highly concordant symmetrical thickening and increased T2 signal intensities in the brachial/lumbosacral plexus, femoral, or sciatic nerves in five of the eight patients with a final diagnosis of CIDP and none of the healthy controls. There were no treatment‐related imaging changes in five patients with CIDP who completed a follow‐up study. Diffuse, symmetrical thickening, and increased T2 signal in root, plexus, and peripheral nerves were found in two patients ultimately excluded due to a diagnosis of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome in addition to signal changes in the muscles, bony lesions, organomegaly, and lymphadenopathy.Discussion: Whole‐body MRN imaging shows promise in detecting abnormalities in proximal nerve segments in patients with CIDP. Future studies evaluating the role of MRN in assessing treatment response should consider follow‐up scans after treatment durations of more than 4 months.
- 3 May 2024
- Published by Wiley in Muscle & Nerve
- Vol. 70 (1) , 101-110
Open AccessWhole‐body magnetic resonance neurography in patients with chronic inflammatory demyelinating polyneuropathy
Introduction/Aims: Whole‐body magnetic resonance neurography (MRN) is an imaging modality that shows peripheral nerve signal change in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). We aimed to explore the diagnostic potential of whole‐body MRN and its potential as a monitoring tool after immunotherapy in treatment‐naïve CIDP patients.Methods: Whole‐body MRN using coronal 3‐dimensional short tau inversion recovery (STIR) sampling perfection with application‐optimized contrasts by using different flip angle evolution (SPACE) techniques was performed in patients being investigated for CIDP and in healthy controls. Baseline clinical neuropathy scales and electrophysiologic parameters were collected, and MRN findings were compared before and after CIDP treatment.Results: We found highly concordant symmetrical thickening and increased T2 signal intensities in the brachial/lumbosacral plexus, femoral, or sciatic nerves in five of the eight patients with a final diagnosis of CIDP and none of the healthy controls. There were no treatment‐related imaging changes in five patients with CIDP who completed a follow‐up study. Diffuse, symmetrical thickening, and increased T2 signal in root, plexus, and peripheral nerves were found in two patients ultimately excluded due to a diagnosis of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome in addition to signal changes in the muscles, bony lesions, organomegaly, and lymphadenopathy.Discussion: Whole‐body MRN imaging shows promise in detecting abnormalities in proximal nerve segments in patients with CIDP. Future studies evaluating the role of MRN in assessing treatment response should consider follow‐up scans after treatment durations of more than 4 months.
- 27 February 2024
- Published by Wiley in Muscle & Nerve
- Vol. 70 (1) , 52-59
Chronic glucocorticoid management in neuromuscular disease: A survey of neuromuscular neurologists
Introduction/Aims: Glucocorticoids (GC) are first-line therapy for many neuromuscular diseases. There is a lack of guidelines regarding the prevention and management of GC complications in the context of neuromuscular disease, introducing the potential for practice variation, that may compromise quality of care. Our aim was to evaluate the practice patterns among Canadian adult neuromuscular neurologists on the screening, management, and treatment of GC-related complications and to identify variances in practice. Methods: A web-based anonymous questionnaire was disseminated to 99 Canadian adult neuromuscular neurologists. Questions addressed patterns of screening, prevention, monitoring, and treatment of GC-induced adverse events, including infection prophylaxis, vaccination, bone health, hyperglycemia, and other complications. Results: Seventy-one percent completed the survey. Of those, 52% perform screening blood work prior to initiating GC, 56% screen for infections, and 18% for osteoporosis. The majority monitor glycemic control and blood pressure (>85%). Thirty-two (46%) reported that they do not primarily monitor GC complications, but rather provide recommendations to the primary care physician. Pneumocystis jiroveci pneumonia prophylaxis was never used by 29%, and 29% recommend vaccinations prior to GC initiation. Calcium supplementation was recommended by 80% to prevent osteoporosis. Only 36% were aware of any existing guidelines for preventing GC complications, and 91% endorsed a need for neurology-specific guidelines. Discussion: There is substantial variability in the management of GC adverse effects among neuromuscular neurologists, often not corresponding to limited published literature. Our results support the need for improved education and neurology-specific guidelines to help standardize practice and improve and prevent complications.
- 27 February 2024
- Published by Wiley in Muscle & Nerve
- Vol. 70 (1) , 52-59
Chronic glucocorticoid management in neuromuscular disease: A survey of neuromuscular neurologists
Introduction/Aims: Glucocorticoids (GC) are first-line therapy for many neuromuscular diseases. There is a lack of guidelines regarding the prevention and management of GC complications in the context of neuromuscular disease, introducing the potential for practice variation, that may compromise quality of care. Our aim was to evaluate the practice patterns among Canadian adult neuromuscular neurologists on the screening, management, and treatment of GC-related complications and to identify variances in practice. Methods: A web-based anonymous questionnaire was disseminated to 99 Canadian adult neuromuscular neurologists. Questions addressed patterns of screening, prevention, monitoring, and treatment of GC-induced adverse events, including infection prophylaxis, vaccination, bone health, hyperglycemia, and other complications. Results: Seventy-one percent completed the survey. Of those, 52% perform screening blood work prior to initiating GC, 56% screen for infections, and 18% for osteoporosis. The majority monitor glycemic control and blood pressure (>85%). Thirty-two (46%) reported that they do not primarily monitor GC complications, but rather provide recommendations to the primary care physician. Pneumocystis jiroveci pneumonia prophylaxis was never used by 29%, and 29% recommend vaccinations prior to GC initiation. Calcium supplementation was recommended by 80% to prevent osteoporosis. Only 36% were aware of any existing guidelines for preventing GC complications, and 91% endorsed a need for neurology-specific guidelines. Discussion: There is substantial variability in the management of GC adverse effects among neuromuscular neurologists, often not corresponding to limited published literature. Our results support the need for improved education and neurology-specific guidelines to help standardize practice and improve and prevent complications.
- Open Access
- 1 October 2023
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 9 (5) , e200088
Biallelic SOX8 Variants Associated With Novel Syndrome With Myopathy, Skeletal Deformities, Intellectual Disability, and Ovarian Dysfunction
Background and Objectives The human genome contains ∼20,000 genes, each of which has its own set of complex regulatory systems to govern precise expression in each developmental stage and cell type. Here, we report a female patient with congenital weakness, respiratory failure, skeletal dysplasia, contractures, short stature, intellectual delay, respiratory failure, and amenorrhea who presented to Medical Genetics service with no known cause for her condition. Methods Whole-exome and whole-genome sequencing were conducted, as well as investigational functional studies to assess the effect of SOX8 variant. Results The patient was found to have biallelic SOX8 variants (NM_014587.3:c.422+5G>C; c.583dup p.(His195ProfsTer11)). SOX8 is a transcriptional regulator, which is predicted to be imprinted (expressed from only one parental allele), but this has not yet been confirmed. We provide evidence that while SOX8 was maternally expressed in adult-derived fibroblasts and lymphoblasts, it was biallelically expressed in other cell types and therefore suggest that biallelic variants are associated with this recessive condition. Functionally, we showed that the paternal variant had the capacity to affect mRNA splicing while the maternal variant resulted in low levels of a truncated protein, which showed decreased binding at and altered expression of SOX8 targets. Discussion Our findings associate SOX8 variants with this novel condition, highlight how complex genome regulation can complicate novel disease-gene identification, and provide insight into the molecular pathogenesis of this disease.
- 1 October 2023
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 9 (5) , e200088
Open AccessBiallelic SOX8 Variants Associated With Novel Syndrome With Myopathy, Skeletal Deformities, Intellectual Disability, and Ovarian Dysfunction
Background and Objectives The human genome contains ∼20,000 genes, each of which has its own set of complex regulatory systems to govern precise expression in each developmental stage and cell type. Here, we report a female patient with congenital weakness, respiratory failure, skeletal dysplasia, contractures, short stature, intellectual delay, respiratory failure, and amenorrhea who presented to Medical Genetics service with no known cause for her condition. Methods Whole-exome and whole-genome sequencing were conducted, as well as investigational functional studies to assess the effect of SOX8 variant. Results The patient was found to have biallelic SOX8 variants (NM_014587.3:c.422+5G>C; c.583dup p.(His195ProfsTer11)). SOX8 is a transcriptional regulator, which is predicted to be imprinted (expressed from only one parental allele), but this has not yet been confirmed. We provide evidence that while SOX8 was maternally expressed in adult-derived fibroblasts and lymphoblasts, it was biallelically expressed in other cell types and therefore suggest that biallelic variants are associated with this recessive condition. Functionally, we showed that the paternal variant had the capacity to affect mRNA splicing while the maternal variant resulted in low levels of a truncated protein, which showed decreased binding at and altered expression of SOX8 targets. Discussion Our findings associate SOX8 variants with this novel condition, highlight how complex genome regulation can complicate novel disease-gene identification, and provide insight into the molecular pathogenesis of this disease.